The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience.
Autologous stem cell transplantation
Chemo-mobilization
Cyclophosphamide
Mobilization
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
01
02
2021
revised:
08
06
2021
accepted:
12
06
2021
pubmed:
22
6
2021
medline:
15
10
2021
entrez:
21
6
2021
Statut:
ppublish
Résumé
We report the outcomes of 117 patients with newly diagnosed multiple myeloma who received novel agent induction, had a poor response to induction, and were mobilized using intravenous intermediate-dose cyclophosphamide (82%) or VD-PACE (18%) plus granulocyte colony-stimulating factor (G-CSF) and on-demand plerixafor. The median progression-free survival and overall survival of the chemo-mobilized cohort were 21 months (95% confidence interval [CI], 15-71) and 58 months (95% CI, 47-80), respectively. We compared our cohort to a 117-patient cohort matched by the level of response at pretransplant evaluation. The matched patients were mobilized with G-CSF and on-demand plerixafor without chemotherapy. Patients receiving chemo-mobilization had higher stem cell yields than the growth-factor-only cohort (median, 10.7 × 10
Identifiants
pubmed: 34153504
pii: S2666-6367(21)01000-9
doi: 10.1016/j.jtct.2021.06.016
pmc: PMC8403627
mid: NIHMS1716560
pii:
doi:
Substances chimiques
Heterocyclic Compounds
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
770.e1-770.e7Subventions
Organisme : NCI NIH HHS
ID : P50 CA186781
Pays : United States
Informations de copyright
Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Références
Bone Marrow Transplant. 2021 Feb;56(2):395-399
pubmed: 32796951
Lancet Haematol. 2020 Jun;7(6):e456-e468
pubmed: 32359506
Bone Marrow Transplant. 2013 Nov;48(11):1444-9
pubmed: 23749109
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Bone Marrow Transplant. 2020 Dec;55(12):2254-2260
pubmed: 32447348
J Oncol Pharm Pract. 2021 Mar;27(2):340-349
pubmed: 32356687
Haematologica. 2002 Oct;87(10):1041-5
pubmed: 12368158
Biol Blood Marrow Transplant. 2018 Feb;24(2):276-281
pubmed: 29037891
Bone Marrow Transplant. 2016 Mar;51(3):372-6
pubmed: 26437056
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
Biol Blood Marrow Transplant. 2020 May;26(5):876-883
pubmed: 31785375
Bone Marrow Transplant. 2021 Aug;56(8):1876-1887
pubmed: 33753907
Blood. 2001 Oct 1;98(7):2059-64
pubmed: 11567990
Bone Marrow Transplant. 1996 Jun;17(6):937-41
pubmed: 8807097
Bone Marrow Transplant. 2009 Apr;43(8):619-25
pubmed: 18997825
Bone Marrow Transplant. 2001 Apr;27(8):837-42
pubmed: 11477441
Bone Marrow Transplant. 2020 Nov;55(11):2132-2137
pubmed: 32358546
Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):602-609
pubmed: 32457024
Transfus Apher Sci. 2020 Oct;59(5):102819
pubmed: 32499108
N Engl J Med. 2017 Apr 6;376(14):1311-1320
pubmed: 28379796
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115
Blood Rev. 2021 May;47:100771
pubmed: 33213986
Am J Hematol. 2020 May;95(5):548-567
pubmed: 32212178
Transfus Apher Sci. 2020 Jun;59(3):102722
pubmed: 32014363
Leukemia. 2007 Sep;21(9):2035-42
pubmed: 17581613
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Biol Blood Marrow Transplant. 2014 Feb;20(2):222-8
pubmed: 24211319
Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308
pubmed: 24141007
J Clin Apher. 2016 Oct;31(5):423-8
pubmed: 26340986
J Natl Compr Canc Netw. 2020 Dec 02;18(12):1685-1717
pubmed: 33285522
N Engl J Med. 2003 May 8;348(19):1875-83
pubmed: 12736280
Leuk Lymphoma. 2016;57(6):1389-97
pubmed: 26428939
Bone Marrow Transplant. 2014 Feb;49(2):201-5
pubmed: 24185588